Articles On Imugene (ASX:IMU)

Fickle fashion trends don’t just apply to apparel. While still a hot sector, cell therapies have suffered from hyped-up expectations, clinical setbacks and high development and manufacturing costs. Arovella Therapeutics (ASX:ALA) chief Dr M...

Highlights  Technology and Real Estate sectors showed strong performance, leading market gains.  Materials sector declined sharply, impacted by falling iron ore prices.  West Wits Mining (WWI) surged after a financing update for its S...

ASX flat despite tech rally Uranium miners gain further after Cameco suspends production Canada’s PM Justin Trudeau set to resign amid mounting pressure   The ASX closed flattish on Monday despite a tech rally. The tech sector rose follow...

The Gold Road Resources Ltd (ASX: GOR) share price is on the slide on Monday morning. In early trade, the ASX 200 gold stock is down 1.5% to $2.05 Why is this ASX 200 gold stock falling? Investors have been selling the gold miner's shares t...

The Aussie bourse has defied morning expectations for the second time in as many days, closing out all but flat with a 0.03% rise – again going against what ASX 200 futures had originally first predicted (today being a bigger drop). It w...

It has been a great finish to the week for Paladin Energy Ltd (ASX: PDN) shares. In afternoon trade, the ASX uranium stock is up 7% to $8.46. But this gain isn't even the strongest in the industry today. For example, at the time of writing,...

Mining shares are dominating the top 10 risers of the benchmark S&P/ASX 200 Index (ASX: XJO) today. ASX 200 gold shares and uranium shares feature prominently following lifts in their commodity prices. The S&P/ASX 200 Material...

The S&P/ASX 200 Index (ASX: XJO) is fighting hard to end the week on a positive note. In afternoon trade, the benchmark index is up 0.4% to 8,232.7 points. Four ASX shares that are rising more than most today are listed below. Here's w...

Highlights Imugene has dosed the first Australian patient in its Phase 1b azer-cel clinical trial at Sydney's Royal Prince Alfred Hospital. U.S. cohort results showed three patients achieved complete responses (CR) despite previous tre...

Imugene Limited (ASX:IMU) has hit its first important milestone in 2025, dosing its first Australian patient with its allogenic CAR T-cell therapy Azer-cel treatment at the Royal Prince Alfred Hospital in Sydney earlier this week. This d...

Imugene Ltd (ASX: IMU) shares are ending the week on a positive note. In late morning, trade, the ASX small cap stock is up 5% to 4.1 cents. Why is this ASX small cap stock roaring higher? Investors have been bidding the immuno-oncology com...

I'm a little melancholic this morning. Well, as melancholic as a dyed-in-the-wool optimist can be, anyway. It's the last day of our getaway down the NSW South Coast – in a couple of hours, we'll be packed up and on our way. It's...

The ASX 200 is expected to open 0.07% lower at 8,185 points, though after yesterday’s defiant reversal things may change through morning trade. Futures tipping a drop Down Under comes after the S&P 500 and Nasdaq composite both exten...

S&P/ASX All Ordinaries Index (ASX: XAO) shares rose by 7.55% and delivered total gross returns, including dividends, of 11.44% last year. That's a pleasing overall market return in anyone's language. But for some stockpickers,...

With more than seven million users moving through HotCopper forums every year, there’s always bound to be some fireside chats – and some companies and stocks definitely shaped as more discussed than others in 2024. Buy now, pay later pla...

Of the 2,200 entities listed on the ASX in 2024, ten stood out by quite a distance on the HotCopper forums as the most-watched stocks of the year. From gas to financial brokers, biotech operators to lithium miners, and even a gold antimo...

Highlights IMU has received confirmation for receipt of AU$11 million R&D tax refund for the 2023 financial year. The refund is anticipated by January 2025. Funds will support the clinical development of Imugene's immuno-oncology...

From artificial intelligence (A.I) to zygotes, the biotech sector this year delivered the A to Z of excitement, intrigue, occasional disappointment and downright disaster. His virtual stethoscope on hand, Dr Boreham was on duty to diagnose...

The S&P/ASX 200 Health Care Index rose 2.89% in November as momentum returned to the sector Health cryogenic services company Vitrafy and nerve-repair biotech Renerve debuted on the ASX  Paradigm Biopharmaceuticals rose 151% in Novembe...

As most ASX investors would be aware, the stock market has had a very lucrative year over 2024 so far. As it currently stands, the S&P/ASX 200 Index (ASX: XJO) has gained a significant 11.6% or so over the year thus far. Thanks to this...

It's a big day for Core Lithium Ltd (ASX: CXO) shares today. Not because of any outsized share price moves. Though shares in the All Ordinaries Index (ASX: XAO) lithium stock are up a welcome 1% at time of writing, trading for 9.3 ce...

Income investors certainly have a lot of choice on the Australian share market. So much so, it can be hard to decide which ASX dividend stocks to buy over others. To narrow things down, let's look at a couple of buy-rated dividend stocks th...

Highlights    Enhanced understanding of SCLC subtypes drives tailored treatment approaches.   Immunotherapy and antibody-drug conjugates emerge as key strategies.   Asia-Pacific region identified as a critical area for further clinica...

The market may be nearing a record high, but that doesn't mean there aren't big potential gains to be made. For example, the ASX 200 share in this article, which is swimming in cash, has been tipped rise very strongly from current levels. W...

Fresh from news of a “complete response” from other clinical trials last week, Imugene has now dosed the first patient with a drug combination that seeks to expose and target difficult-to-treat solid cancers.

The ASX200 has been down 0.4% at 8,261 points. Investors reacted with disappointment to the latest Chinese stimulus measures released on the weekend. Declining iron ore and oil prices has adversely affected commodity stocks, as hopes of...

Highlights First patient has been dosed in the intratumoural combination arm of the OASIS trial. The patient with colorectal cancer was dosed at Northwestern University. As part of the OASIS trial, the company intends to expand to 10...

The S&P/ASX 200 Index (ASX: XJO) enjoyed an enthusiastic end to the trading week this Friday, giving investors a tangible boost as we head into the weekend. After spending all day in positi...

In an Australian first, clinical cancer researcher and developer Imugene will launch its “azer-cel” trial against a difficult-to-treat form of non-Hodgkins lymphoma at Sydney’s Royal Prince Alfred Hospital.

Both Wesfarmers Ltd (ASX: WES) shares and Sigma Healthcare Ltd (ASX: SIG) shares offer investors exposure to the pharmacy sector. Wesfarmers may be best known for its divisions like Bunnings, Kmart, and Officeworks, but it also owns Aust...

The Mineral Resources Ltd (ASX: MIN) share price has been volatile in 2024 and is down nearly 45% this year. Shares have slipped nearly 28% in the past month alone, with investor confidence shaken by revelations into co-founder Chris El...

Imugene Ltd (ASX:IMU) has opened the first Australian site for its clinical trial testing a therapy for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) – a difficult form of non-Hodgkin’s lymphoma. The company will carry out...

The S&P/ASX 200 Index (ASX: XJO) is having a great finish to the week. In afternoon trade, the benchmark index is up 0.9% to 8,299.4 points. Four ASX shares that are rising more than most are listed below. Here's why they are charging...

Highlights The first Australian site for the azer-cel Phase 1b trial is now open. Patient recruitment will start at Royal Prince Alfred Hospital in Sydney in November 2024. The azer-cel Phase 1b trial is currently the only allogeneic...

The Core Lithium Ltd (ASX: CXO) share price is surging higher today. Shares in the All Ordinaries Index (ASX: XAO) lithium stock closed yesterday trading for 11 cents. In morning trade on Wednesday, shares are swapping hands for 11.8 ce...

Many of Australia's top brokers have been busy adjusting their financial models and recommendations again. This has led to the release of a number of broker notes this week. Three ASX shares that brokers have named as buys this week are lis...

ASX healthcare stocks underperform but optimism grows Uscom, Respiri and Hitiq report mixed results Artrya and Nyrada make key clinical advances   The S&P/ASX 200 Health Care [XHJ] index was down 0.9% gain in October. For the year, th...

The S&P/ASX 200 Index (ASX: XJO) endured a tough day of trading this Tuesday as ASX investors pulled back from the optimism that we saw yesterday to kick off the trading week. By the time the...

Aussie shares slip as RBA holds rates steady MinRes rebounds, Domino’s Don Meij quits Investors rethink Trump comeback as Harris leads in Iowa   Aussie shares slipped into the red on Tuesday, falling 0.4% as sentiment remained subdued aft...

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated. Dividends have played an integral role in many S&P 500 companies. The payouts serve as a stabilizing force in such stocks, and...

It's fair to say that ASX 300 property stock Lifestyle Communities Ltd (ASX: LIC) has not had a great year so far in 2024. As it stood yesterday afternoon, Lifestyle Communities shares were down a painful 53% or so this year. Yep, this prop...

The S&P/ASX 200 Index (ASX: XJO) is out of form on Tuesday and dropping into the red. In afternoon trade, the benchmark index is down 0.4% to 8,132.7 points. Four ASX shares that are not letting that hold them back are listed below. He...

Clinical-stage immuno-oncology company Imugene is celebrating more than two years’ “complete response” for one of its bile tract cancer trial therapy subjects in its CF33 MAST VAXINIA study.

ASX exchange-traded funds (ETFs) have surged in popularity over the past few years, especially among younger investors. They offer a quick and easy way to achieve instant diversification by purchasing a basket of ASX shares or internati...

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated. Looking at Wall Street analysts' price targets can be a worthy exercise, because it may identify some stocks with huge upsides you...

Highlights In the Phase 1 MAST trial for VAXINIA, a bile tract cancer patient has maintained a complete response for over two years. The Bile Tract Cancer Expansion phase has cleared its first cohort with no dose limiting toxicities, a...

Those who own ASX shares face an existential trilemma: how much cash to hold, how to finance new investments, and when to sell existing ones. Cash has to come from somewhere to purchase new assets. Keeping cash on the sidelines is one w...

Imugene Ltd (ASX: IMU) shares are having a strong start to the session on Tuesday. At the time of writing, the ASX 300 stock is up 11% to 4.9 cents. Why is this ASX 300 stock jumping? The catalyst for today's strong gain has been the releas...

Imugene (ASX:IMU), a clinical-stage immuno-oncology company, has reported a significant achievement in its Phase 1 MAST (Metastatic Advanced Solid Tumours) trial. The company announced that a patient with bile tract cancer has now maintaine...

Shares in the embattled Star Entertainment Group Ltd (ASX: SGR) extended losses on Monday and finished the session nearly 7% in the red. The stock now fetches 21 cents apiece, bringing losses to more than 20% over the past week and nearl...